UNSPSC 51111734: Butantrone

This classification denotes an anthraquinone compound with the molecular formula C18H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P148IBA8M, chemically known as 10-butyryl-1,8-dihydroxyanthrone but generally known as butantrone, which bears US NIH Compound Identifier 53271. European Medicines Agency schedules Butantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06006MIG.

UNSPSC 51111734 Butantrone is a Commodity code that does not align with the state and local procurement activity currently tagged under it. The recent solicitations show no purchases of butantrone, a pharmaceutical precursor. Instead, the opportunities tagged to this code reflect naloxone procurement, generic pharmaceutical supply agreements, medical and first aid supplies for emergency responders, and exploratory pharmacy benefit management initiatives—none of which involve butantrone as a line item or service. The mismatch suggests either a data-quality issue in the tagging or a category that has drifted from its nominal scope in state and local practice.

The issuing bodies in the recent record include a county health department (Seminole County, Florida), a state health agency (Texas HHS Commission), a city fire department (Tampa Fire Department via the City of Tampa), and a regional cooperative purchasing alliance (MMCAP serving Minnesota and participating jurisdictions including Oregon). Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon, with the most recent opportunities posted between January and June 2026. Representative recent work includes Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (response due July 26, 2023), Tampa's IFB for 169 line items of medical and first aid supplies for emergency responders with an estimated contract value of $700,000 and a sheltered Small Local Business Enterprise set-aside (response due March 13, 2026), Minnesota's RFP for generic pharmaceuticals and OTC products through authorized wholesalers (response due March 26, 2026), and Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response due April 3, 2026). Given the absence of butantrone-specific demand, this code does not represent a meaningful pursuit opportunity in current state and local procurement.